Method for the in vitro diagnosis of a neurodegenerative disease
AssigneesUniversite Grenoble Alpes, Institut National de la Sante et de la Recherche Medicale
InventorsMuriel-Réjane JACQUIER-SARLIN, Alain BUISSON
Life of this patent
Estimating the term…
Abstract
A method for the in vitro diagnosis of a neurodegenerative disease, in a human or animal individual, at an early stage, including the step which includes in detecting the presence of at least one marker chosen from the derived forms of amyloid beta (Aβ) peptides selected from the oligomers of said peptides and the prefibrillar and fibrillar aggregated forms of said peptides, and the derived forms of phosphorylated tau proteins selected from the hyperphosphorylated forms of said proteins, the aggregated forms of said proteins and the modified phosphorylated tau proteins resulting from one or several post-translational modifications, the presence of the marker(s) being detected in a stool sample of said individual.
Claims15
-17. (canceled)
A method for the in vitro diagnosis of a neurodegenerative disease, comprising the following steps
- detecting the presence of at least one marker in a stool sample of an individual
- the individual being a human or animal at an early stage of the neurodegenerative disease,
- the marker is chosen from the derived forms of phosphorylated tau proteins selected from the hyperphosphorylated forms of the proteins, the aggregated forms of the proteins and the modified phosphorylated tau proteins resulting from one or several post-translational modifications.
A method for monitoring the condition of a human or animal individual suspected of suffering from a neurodegenerative disease, comprising the following steps:
- breaking into contact a first stool sample of the individual with at least one antibody or antibody portion specifically recognizing at least one marker chosen from phosphorylated tau proteins and the derived forms of the proteins, and forming a complex between the antibody or antibody portion and the marker,
- measuring the content of the complex in the first sample,
- then taking a second stool sample of the individual, the second sample being taken after the first sample
- breaking into contact the second stool sample with the antibody or antibody portion, and forming a complex between the antibody or antibody portion and the marker,
- measuring the content of the complex in the second sample,
- a variation between the contents of the complex in the first sample and of the complex in the second sample indicating a progression of the disease or a regression of the disease
- a content of the complex in the second sample higher than the content of this same complex in the first sample indicates a progression of the disease, at an early stage,
- a content of the complex in the second sample lower than the content of this same complex in the first sample indicates a regression of the disease.
A method for screening a drug for treating a neurodegenerative disease, in an individual suspected of suffering from such a disease, comprising the following steps:
- breaking into contact a first stool sample of the individual with at least one antibody or antibody portion specifically recognizing at least one marker chosen from phosphorylated tau proteins and the derived forms of the proteins, and forming a complex between the antibody or antibody portion and the marker,
- measuring the content of the complex in the first sample,
- then taking a second stool sample of the individual, the second sample being taken after the first sample
- breaking into contact the second stool sample with the antibody or antibody portion, and forming a complex between the antibody or antibody portion and the marker,
- measuring the content of the complex in the second sample,
- a variation between the contents of the complex in the first sample and of the complex in the second sample indicating the effectiveness or ineffectiveness of the drug,
- a content of the complex in the second sample lower than the content of this complex in the first sample indicates an effectiveness of the drug.
A kit for the in vitro detection of a neurodegenerative disease, at the early stage, of a human or animal individual, comprising
- at least one antibody or antibody portion specifically recognizing at least one marker chosen from the derived forms of phosphorylated tau proteins selected from the hyperphosphorylated forms of the proteins, the aggregated forms of the proteins and the modified phosphorylated tau proteins resulting from one or several post-translational modifications, and
- the means allowing the formation of a complex between the antibody or antibody portion and the marker.
Dependencies are inferred from the claim text.